Skip to content

The Effect on Decreasing Chemotherapeutic Toxicity and Increasing Anti-tumor Effect of Chinese Herbs Based on Syndrome Differentiation

Status
UNKNOWN
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02737735
Enrollment
200
Registered
2016-04-14
Start date
2016-03-31
Completion date
2020-01-31
Last updated
2016-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Brief summary

To study the effect on decreasing chemotherapeutic toxicity and increasing anti-tumor treatment of Chinese Herbs based on syndrome differentiation

Interventions

DRUGstandard chemotherapy medicine combined with Chinese herbs
DRUGstandard chemotherapy medicine

Sponsors

First Affiliated Hospital, Sun Yat-Sen University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Histology and cytology diagnosed IIIB or IV non-small-cell lung cancer (NSCLC) and untreated; Age \> 18 ages * Sex unlimited; ECOG (Eastern Cooperative Oncology Group) fitness score (Performance status, PS)≤2. * White blood cell count ≥ 3 x 10E9 / L, neutrophils ≥1 x 109 p/L, hemoglobin≥80 g/L , platelet ≥100 x 10E9 / L * ALT, AST, normal or less than 2 times, bilirubin is normal * Serum level in the normal range;Thr ecg is normal * Expected survival time≥ 3 months or more; * Agreed to the treatment combined traditional Chinese medicine with western medicine

Exclusion criteria

* Engaged in other clinical subjects * Pregnant or lactating women, women in childbearing age refuse contraceptives during the trail * Severe pneumonia, tuberculosis, lung abscess, myocarditis and other malignant tumor * Severe damage of heart, liver and kidney (cardiac function grade 3 \ 4, ALT and/or AST 2 times more than normal , Cr more the normal limit) * Mental illness, Refused to partner; Cannot obtain informed consent

Design outcomes

Primary

MeasureTime frame
Overall survival rate36months
progression-free survival rate36months

Other

MeasureTime frame
KPS scores36months
nutritional evaluation scores36months
BMS(Bone marrow suppression) scores36months
Gastrointestinal reactions scores36months
Quality of Life Questionnaire (EORTC QLQ C30)scores36months
AST value36months
ALT value36months
creatinine value36months
hair loss level scores36months
RECIST(Response Evaluation Criteria In Solid Tumors)36months

Countries

China

Contacts

Primary ContactBao-guo Sun, doctor
Sunbaoguo666@126.com13316134352
Backup ContactXin Zhou, master
myeva520@163.com13533259616

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026